Search
Cholecystokinin
go.drugbank.com/drugs/DB08862ApprovedInvestigationalWithdrawnRecent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.
Leucine-rich repeat serine/threonine-protein kinase 2
go.drugbank.com/bio_entities/BE0009457TargetHumansSerine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:2185...
Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 2F-box-like/WD repeat-containing protein TBL1X
go.drugbank.com/bio_entities/BE0012106TargetHumansF-box-like protein involved in the recruitment of the ubiquitin/19S proteasome complex to nuclear receptor-regulated transcription units (PubMed:14980219). … Probably acts as integral component of corepressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the subsequent proteasomal degradation of transcription repressor complexes
Polypeptides: F-box-like/WD repeat-containing protein TBL1XZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalof oral zavegepant (150 mg bid) in subjects with mild allergic asthma. … [A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults.
Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Chromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: ADDAMEL N 20 AMPUL, M T E 4 Concentrate InjCategories: Compounds used in a research, industrial, or household settingDimethicone 410
go.drugbank.com/drugs/DB14005Approved[L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%. … It is reported that the term dimethicone includes the notation of polydimethylsiloxane and trimethylsiloxy-terminated fluids between 20-30,000 cSt (viscosity).[L2163]
Clove oil
go.drugbank.com/drugs/DB11338ApprovedNutraceuticalClove is native of Indonesia but is now cultured in several parts of the world, including Brazil in the state of _Bahia_. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.
Mixtures: New Skin Clear Spray Bandage, New Skin Clear Liquid BandageCategories: Complex MixturesSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalSamidorphan has been shown in animal models and clinical trials to ameliorate [olanzapine]-induced weight gain and metabolic dysfunction. … [A235623, A235638, L34359] Although antipsychotic-induced weight gain is incompletely understood, it is thought that the opioid system plays a key role in feeding and metabolism, such that opioid antagonism
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized